Bristol-Myers Squibb (NYSE:BMY) updated its FY 2019 earnings guidance on Thursday. The company provided EPS guidance of $4.10-4.20 for the period.
Several analysts recently weighed in on the stock. BMO Capital Markets reiterated a buy rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday. ValuEngine upgraded shares of Bristol-Myers Squibb from a sell rating to a hold rating in a research report on Friday, December 7th. Barclays lifted their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an equal weight rating in a research report on Friday, October 12th. Credit Suisse Group restated a hold rating and set a $61.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 12th. Finally, William Blair restated an outperform rating on shares of Bristol-Myers Squibb in a research report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of Hold and a consensus target price of $61.56.
Shares of BMY opened at $52.43 on Thursday. The company has a market capitalization of $84.84 billion, a PE ratio of 17.42, a price-to-earnings-growth ratio of 1.36 and a beta of 0.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. Bristol-Myers Squibb has a 12-month low of $46.94 and a 12-month high of $70.05.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 4th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, January 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.13%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. Bristol-Myers Squibb’s payout ratio is currently 53.16%.
ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb (BMY) Issues FY 2019 Earnings Guidance” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4055211/bristol-myers-squibb-bmy-issues-fy-2019-earnings-guidance.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Further Reading: What Does Beta Mean In Stock Selection
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.